IceCure Medical Updates FDA Progress for ProSense Breast Cancer Device
Ticker: ICCM · Form: 6-K · Filed: Mar 20, 2025 · CIK: 1584371
Sentiment: neutral
Topics: regulatory-update, medical-device, fda
TL;DR
IceCure Medical's ProSense breast cancer device is moving forward with FDA, potential submission H2 2025.
AI Summary
On March 20, 2025, IceCure Medical Ltd. announced an updated timeline and progress with the FDA regarding marketing authorization for its ProSense system in early-stage breast cancer. The company is working towards a potential FDA submission in the second half of 2025.
Why It Matters
This update is crucial for patients and oncologists as it signals potential advancements in minimally invasive treatments for early-stage breast cancer, pending regulatory approval.
Risk Assessment
Risk Level: medium — Regulatory approval processes can be lengthy and uncertain, impacting the company's timeline and market entry.
Key Numbers
- H2 2025 — Potential FDA Submission (Indicates the expected timeframe for IceCure Medical's next step in the regulatory process.)
Key Players & Entities
- IceCure Medical Ltd. (company) — Filer of the report and developer of ProSense
- ProSense (product) — Medical device for early-stage breast cancer
- FDA (company) — Regulatory body reviewing the ProSense device
- March 20, 2025 (date) — Date of the press release and filing
FAQ
What is the specific status of the FDA's review for ProSense?
The filing indicates updated timeline and progress with the FDA, but does not detail the specific status of the review beyond working towards a potential submission in H2 2025.
What is the ProSense system used for?
The ProSense system is intended for marketing authorization for early-stage breast cancer treatment.
When does IceCure Medical expect to submit to the FDA?
IceCure Medical is working towards a potential FDA submission in the second half of 2025.
What type of report is this filing?
This is a Form 6-K, Report of Foreign Private Issuer.
What is the company's principal executive office located?
The company's principal executive office is located in Caesarea, Israel.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 20, 2025 regarding IceCure Medical Ltd. (ICCM).